In The News: School of Integrated Health Sciences
Those missions, which had a successful kickoff with Artemis-1, will establish the groundwork for months-long human habitation on the Lunar surface. Proposed base camps will present unique opportunities to test technology, unravel scientific secrets about the Moon's past and present, search for the presence of water, and more.
AB Science is initiating a Phase 3 trial to evaluate the safety and efficacy of its candidate therapy masitinib in patients with mild to moderate Alzheimer’s disease.
Biopharmaceutical company Axsome Therapeutics Inc. (AXSM:NASDAQ), which is focused on developing new medicines for use in the treatment of central nervous system (CNS) disorders, today announced that "AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD (Assessing Clinical Outcomes in Alzheimer's Disease Agitation) Phase 3 trial, by substantially and statistically significantly delaying the time to relapse and preventing relapse of agitation in patients with Alzheimer's disease, as compared to placebo."
Newly announced findings from the phase 3 ACCORD trial (NCT04797715) showed that AXS-05 (Axsome Therapeutics), a novel, investigational n-methyl-D-aspartate (NMDA) receptor antagonist, met its primary end point of statistically significant delay in time to relapse and preventing relapse of agitation in patients with Alzheimer disease (AD) agitation.1
Diet trends go in and out of style, but intermittent fasting has been a buzzy diet among celebs for a while. Plenty of people swear by the health and weight loss benefits. Still, even the same weight-loss method can work differently from person to person, you may be wondering whether there is a best way to do intermittent fasting for women and get the most out of your efforts.
A new study that is being presented this week at the American College of Cardiology Middle East 2022 Together With the 13th Emirates Cardiac Society Congress, reports that eating more refined grains was linked with a greater risk for premature coronary artery disease (PCAD).
Alzheimer’s disease is a progressive neurological disorder that leads to brain atrophy and death of its cells. It is the most common cause of dementia. It leads to a persistent decrease in the ability to think, and in behavioral and social skills; This limits a person’s ability to live independently.
According to a new study published this month in the Journal of Affective Disorders, vegetarians experienced depressive episodes twice as often as those who ate meat.
Drugmakers Biogen and Eisai say their experimental drug lecanemab slowed the progress of Alzheimer’s disease in a large human study the companies did.
As far as UNLV students go, she was older, in her 30s. McKenzie Mayor remembers sensing despair. The woman likely had lost her job, money was tight, Mayor thought.
An experimental Alzheimer's drug made by Eisai Co Ltd (4523.T) and Biogen (BIIB.O) slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.
An experimental Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.